Logo

BeiGene and EUSA Receive NMPA’s Approval of Sylvant (siltuximab) in China for Idiopathic Multicentric Castleman Disease

Share this

BeiGene and EUSA Receive NMPA’s Approval of Sylvant (siltuximab) in China for Idiopathic Multicentric Castleman Disease

Shots:

  • The approval is based on the P-II trial to evaluate siltuximab vs PBO in 79 patients with iMCD across 19 countries including 16 patients from China
  • The 1EPs of the study were durable tumor & symptomatic response with a significant difference in both responses (34% vs 0%) & complete resolution or stabilization of iMCD symptoms @18wks. without treatment failure. A subgroup analysis showed no difference in demographic & baseline disease characteristics b/w Asian & overall patient population, efficacy & safety data were consistent with an overall population
  • Siltuximab is a mAb that neutralizes IL-6 in multiple inflammatory conditions & is approved in the US, EU & other countries globally

Ref: Businesswire | Image: BeiGene 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions